A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
The reason for this study is to evaluate the amount of time with glucose values within target range.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year
Participants must be using Dexcom G5 or G6 Continuous Glucose Monitoring (CGM) and with a total CGM use 6 months in the prior year
Participants must have been on the same type of short acting insulin (Humalog U-100 or Novolog) for at least 30 days prior to screening
Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening
Participants Must Not:
Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening
Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening
Participants must not be taking certain diabetes medications that are not allowed for study participation
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo